Trial Information

Summary: PHII-73 NCI #7518: A Phase II Study of VEGF Trap (NSC 724770) in Patients with MDS

You have been asked to participate in this research study because you are have myelodysplasic syndrome (MDS) of a grade defined as requiring transfusion support and/or not responding to other therapies.  The purpose of this study is evaluate the effects of the investigational agent VEGF Trap against MDS in terms of improvement in blood tests, overall survival, and progression (worsening of disease).  The study will also evaluate the side effects of VEGF Trap.  In addition, laboratory studies will be done to better understand the effects on MDS.  Your participation in this study is expected to last a minimum of one cycle of treatment (14 days).  If you are tolerating treatment and your medical condition is not getting worse, you will be able to receive additional cycles of treatment.  After you discontinue treatment, you will be followed for approximately 6 weeks for follow-up.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:41:38 PM